137 related articles for article (PubMed ID: 27033222)
21. Human peripheral blood CD4 T cell-engrafted non-obese diabetic-scid IL2rγ(null) H2-Ab1 (tm1Gru) Tg (human leucocyte antigen D-related 4) mice: a mouse model of human allogeneic graft-versus-host disease.
Covassin L; Laning J; Abdi R; Langevin DL; Phillips NE; Shultz LD; Brehm MA
Clin Exp Immunol; 2011 Nov; 166(2):269-80. PubMed ID: 21985373
[TBL] [Abstract][Full Text] [Related]
22. Donor T cells administered over HLA class II barriers mediate antitumor immunity without broad off-target toxicity in a NOD/scid mouse model of acute leukemia.
Stevanović S; Nijmeijer BA; van Schie ML; Salvatori DC; Maas S; Griffioen M; Falkenburg JH
Biol Blood Marrow Transplant; 2013 Jun; 19(6):867-75. PubMed ID: 23500532
[TBL] [Abstract][Full Text] [Related]
23. Antileukemia and antitumor effects of the graft-versus-host disease: a new immunovirological approach.
Sinkovics JG
Acta Microbiol Immunol Hung; 2010 Dec; 57(4):253-347. PubMed ID: 21183421
[TBL] [Abstract][Full Text] [Related]
24. Xenogeneic Graft-Versus-Host Disease in Humanized NSG and NSG-HLA-A2/HHD Mice.
Ehx G; Somja J; Warnatz HJ; Ritacco C; Hannon M; Delens L; Fransolet G; Delvenne P; Muller J; Beguin Y; Lehrach H; Belle L; Humblet-Baron S; Baron F
Front Immunol; 2018; 9():1943. PubMed ID: 30214443
[TBL] [Abstract][Full Text] [Related]
25. Prevention of acute graft-versus-host disease by humanized anti-CD26 monoclonal antibody.
Hatano R; Ohnuma K; Yamamoto J; Dang NH; Yamada T; Morimoto C
Br J Haematol; 2013 Jul; 162(2):263-77. PubMed ID: 23692598
[TBL] [Abstract][Full Text] [Related]
26. Preclinical Testing of Antihuman CD28 Fab' Antibody in a Novel Nonhuman Primate Small Animal Rodent Model of Xenogenic Graft-Versus-Host Disease.
Hippen KL; Watkins B; Tkachev V; Lemire AM; Lehnen C; Riddle MJ; Singh K; Panoskaltsis-Mortari A; Vanhove B; Tolar J; Kean LS; Blazar BR
Transplantation; 2016 Dec; 100(12):2630-2639. PubMed ID: 27861291
[TBL] [Abstract][Full Text] [Related]
27. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
[TBL] [Abstract][Full Text] [Related]
28. The effect of human IL-2-activated natural killer and T cells on graft-versus-host disease and graft-versus-leukemia in SCID mice bearing human leukemic cells.
Xun CQ; Thompson JS; Jennings CD; Brown SA
Transplantation; 1995 Oct; 60(8):821-7. PubMed ID: 7482742
[TBL] [Abstract][Full Text] [Related]
29. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
Talmadge JE
Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
[TBL] [Abstract][Full Text] [Related]
30. Human regulatory T cells control xenogeneic graft-versus-host disease induced by autologous T cells in RAG2-/-gammac-/- immunodeficient mice.
Mutis T; van Rijn RS; Simonetti ER; Aarts-Riemens T; Emmelot ME; van Bloois L; Martens A; Verdonck LF; Ebeling SB
Clin Cancer Res; 2006 Sep; 12(18):5520-5. PubMed ID: 17000688
[TBL] [Abstract][Full Text] [Related]
31. Suppression of xenogeneic graft-versus-host disease by treatment with immunoglobulin-like transcript 3-Fc.
Vlad G; Stokes MB; Liu Z; Chang CC; Sondermeijer H; Vasilescu ER; Colovai AI; Berloco P; D'Agati VD; Ratner L; Cortesini R; Suciu-Foca N
Hum Immunol; 2009 Sep; 70(9):663-9. PubMed ID: 19501624
[TBL] [Abstract][Full Text] [Related]
32. Effect of epigallocatechin-3-gallate on graft-versus-host disease.
Choi J; Cooper ML; Ziga ED; Ritchey J; DiPersio JF
Cell Transplant; 2014; 23(9):1163-6. PubMed ID: 23676554
[TBL] [Abstract][Full Text] [Related]
33. Rat stem cells developing in irradiated SCID mice fail to become tolerized and cause lethal graft-versus-host disease.
Surh CD; Kosaka H; Sprent J
Am J Pathol; 1997 Aug; 151(2):591-9. PubMed ID: 9250172
[TBL] [Abstract][Full Text] [Related]
34. A new xenograft model for graft-versus-host disease by intravenous transfer of human peripheral blood mononuclear cells in RAG2-/- gammac-/- double-mutant mice.
van Rijn RS; Simonetti ER; Hagenbeek A; Hogenes MC; de Weger RA; Canninga-van Dijk MR; Weijer K; Spits H; Storm G; van Bloois L; Rijkers G; Martens AC; Ebeling SB
Blood; 2003 Oct; 102(7):2522-31. PubMed ID: 12791667
[TBL] [Abstract][Full Text] [Related]
35. Altered donor P2X7 activity in human leukocytes correlates with P2RX7 genotype but does not affect the development of graft-versus-host disease in humanised mice.
Adhikary SR; Geraghty NJ; Cuthbertson P; Sluyter R; Watson D
Purinergic Signal; 2019 Jun; 15(2):177-192. PubMed ID: 31001750
[TBL] [Abstract][Full Text] [Related]
36. Correlation between the kinetics of CD3+ chimerism and the incidence of graft-versus-host disease in patients undergoing allogeneic hematopoietic stem cell transplantation.
Rupa-Matysek J; Lewandowski K; Nowak W; Sawiński K; Gil L; Komarnicki M
Transplant Proc; 2011 Jun; 43(5):1915-23. PubMed ID: 21693300
[TBL] [Abstract][Full Text] [Related]
37. Tolerance induction between two different strains of parental mice prevents graft-versus-host disease in haploidentical hematopoietic stem cell transplantation to F1 mice.
Guo Y; Zhang L; Wan S; Sun X; Wu Y; Yu XZ; Xia CQ
Biochem Biophys Res Commun; 2014 Apr; 446(4):1035-41. PubMed ID: 24661874
[TBL] [Abstract][Full Text] [Related]
38. P2X7 receptor antagonism increases regulatory T cells and reduces clinical and histological graft-versus-host disease in a humanised mouse model.
Cuthbertson P; Geraghty NJ; Adhikary SR; Casolin S; Watson D; Sluyter R
Clin Sci (Lond); 2021 Feb; 135(3):495-513. PubMed ID: 33463682
[TBL] [Abstract][Full Text] [Related]
39. Bone marrow-derived mesenchymal stem cells decrease acute graft-versus-host disease after allogeneic hematopoietic stem cells transplantation.
Tian Y; Deng YB; Huang YJ; Wang Y
Immunol Invest; 2008; 37(1):29-42. PubMed ID: 18214798
[TBL] [Abstract][Full Text] [Related]
40. Multicenter analyses demonstrate significant clinical effects of minor histocompatibility antigens on GvHD and GvL after HLA-matched related and unrelated hematopoietic stem cell transplantation.
Spierings E; Kim YH; Hendriks M; Borst E; Sergeant R; Canossi A; Oudshoorn M; Loiseau P; Dolstra H; Markiewicz M; Leffell MS; Pereira N; Kircher B; Turpeinen H; Eliaou JF; Gervais T; Laurin D; Enczmann J; Martinetti M; Thomson J; Oguz F; Santarone S; Partanen J; Siekiera U; Alessandrino EP; Kalayoglu S; Brand R; Goulmy E
Biol Blood Marrow Transplant; 2013 Aug; 19(8):1244-53. PubMed ID: 23756210
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
